

Alice Di Pasquale, Hannah Moody

Peer reviewed by two members of Breast Cancer UK independent Science Panel

1. Summary

Parabens are Endocrine Disrupting Chemicals (EDCs) used as preservatives to stop the growth of microorganisms in cosmetics, personal care products and some processed foods. They can be ingested or absorbed through the skin and have been found in many body fluids and tissues, including in the breast. In laboratory studies, parabens were found to interfere with the female hormone oestrogen and increase the risk of mammary tumours in animals. However, only a limited number of human studies have been carried out and these are inconclusive regarding the possible link to breast cancer. Nonetheless, exposure to parabens should be reduced by seeking paraben-free cosmetics and personal care products. Regulations should also be tightened, especially for parabens officially recognised to be EDCs. Breast Cancer UK is calling for the phasing out and removal of EDCs from non-essential products.

2. Parabens and their uses

Para-hydroxybenzoic acid and parabens are synthetic chemicals used as preservatives in cosmetics and food to stop the growth of microorganisms [1]. Parabens are also referred to as esters of para-hydroxybenzoic acid and can be produced naturally by plants and bacteria [1].

The most common use for parabens is as preservatives in personal care products, such as shampoos, conditioners, deodorants, creams, lotions and mouthwash [2,3]. Within these products, the most used paraben is methylparaben, whilst butylparaben is the least common [4].




Figure 1. Chemical structure of the parabens. Created with BioRender.com

How to cite: Di Pasquale A., Moody H. Parabens and breast cancer. Breast Cancer UK. 2024. <https://doi.org/10.71450/7864836>

These chemicals have also been found in menstrual and female hygiene products [5] as well as pharmaceuticals and medicines [2]. Although not common in the UK, methylparaben, ethylparaben and their salts can also be used as preservatives in food, mainly in processed and precooked meat, cereal and potato-based snacks, coated nuts, and confectionery [6]. In these products, parabens are listed on the ingredients label as the following E numbers: E214, E215, E218 and E219 [7].

3. Exposure and metabolism

The use of cosmetics and personal care products is the main source of exposure to parabens, which is generally higher in women compared to men and children [8,9]. This group of chemicals can be easily absorbed through the skin and leave-on products, like lotions and make-up, can provide continuous and prolonged exposure [2].

When parabens are ingested, they are rapidly metabolised (broken down) to para-hydroxybenzoic acid and this is eliminated in the urine within 8-12 hours [1,10]. However, when they are absorbed through the skin, they might not be metabolised and can be eliminated in the urine in their original form [11]. For this reason, paraben levels in the urine are linked to the use of cosmetics [10,12], with methylparaben usually found in higher concentrations compared to butylparaben [1].

Parabens have also been measured in

blood, amniotic fluid, cord blood, breast milk and placental and breast tissues [5,13–19]. Studies have shown that exposure to parabens can be effectively reduced by swapping cosmetics and personal care products with EDC-free versions [9,20,21].

However, this may not be sufficient to protect health as parabens have also been found in the environment [5], drinking water [22], river water [23], groundwater [24], soil and sediments [25], aquatic organisms [26], as well as in house dust, and indoor and outdoor urban air [27–29].

4. Parabens in breast tissue

Although parabens may be metabolised shortly after entering the human body, unmetabolised parabens have also been measured in the body and breast tissues [14,30–32]. The analysis of breast tumours found at least one paraben in all of the samples and methylparaben was present in the highest amounts, which is consistent with its widespread use in personal care products [30,31]. Parabens were also measured in 99% of non-cancerous breast tissue samples obtained from patients with breast cancer [14]. Furthermore, when comparing the concentration of parabens in breast cancer tissue with benign breast tumours, the cancerous tissue was found to have higher levels of parabens [32]. This suggests that these chemicals may preferentially accumulate in cancerous tissue, where they could display oestrogenic activity (see Section 5.1) [32].

5. Parabens and breast cancer

Growing evidence shows that parabens are Endocrine Disrupting Chemicals (EDCs) that may interfere with our hormone system, in particular with the female hormone oestrogen [33]. This hormone is responsible for many important biological events that are initiated by binding to oestrogen receptors (ER) in cells [34]. However, high levels of oestrogen can also encourage cells to divide rapidly (a process known as cell proliferation) which can increase the possibility of mutations, including those that lead to breast cancer [35]. Therefore, high levels of oestrogen can increase breast cancer risk [36] and EDCs with oestrogenic properties may play a role in breast cancer [37].

5.1 Cell studies

Laboratory studies have shown that parabens and para-hydroxybenzoic acid have weak oestrogenic activity in both normal and breast cancer cells [4,33,38–45]. By mimicking oestrogen, parabens can directly bind to ERs [1,2,46–49] and regulate gene expression [1,2,49,50], metabolism [51] and increase cell proliferation [1,33,46–48,51].

Their ability to bind to the ER is dependent on their chemical structure and parabens with bigger side chains (Figure 1) bind more strongly and therefore have higher oestrogenic activity [1,4,45,46,49,50]. The order of oestrogenicity of these chemicals, from higher to lower, is as follows:




Figure 2. Parabens (P) can increase the production of oestrogen receptors (ERs) or bind to the ER mimicking oestrogen. After binding to the ER, they can regulate gene expression and increase cell proliferation. Created with BioRender.com

butylparaben > propylparaben > ethylparaben > methylparaben > para-hydroxybenzoic acid [33,52]. However, even the most potent paraben is much weaker than oestrogen, therefore the concentration of parabens needed to have an oestrogenic effect is much higher (at least 100,000 times higher) than that of natural oestrogen [1,33,46].

Nonetheless, studies have shown that parabens may be harmful at concentrations relevant to human exposure [39,48,51,53]. For example, butylparaben was measured in the blood at concentrations that, after accounting for its weaker oestrogenic activity, are similar to the levels of oestradiol (a potent form of oestrogen) in the breast (Figure 3) [11,54]. Furthermore, when



Figure 3. In people using cosmetics containing butylparaben levels as high as 135 ng ml^{-1} were measured in the blood [54]. After adjusting for the weaker activity of butylparaben, this is equivalent to having 13.5 pg ml^{-1} of oestradiol. With normal levels of oestradiol in the breast tissue being about 55 pg ml^{-1} , this suggests that levels of butylparaben relevant to human exposure may have oestrogenic effects, especially when considering mixtures [11]. Created with BioRender.com

multiple parabens are present their activity can be added together, as they act with the same mechanism, resulting in oestrogenic effects in breast cancer cells [55]. The same additive effect was also observed for cocktails of parabens with other EDCs, including other preservatives used in cosmetics [41,42].

Parabens may also show oestrogenic properties by acting through other mechanisms that do not require direct binding to the ER [49]. These include increasing the expression (or production) of hormone receptors [39,46] or interfering with the synthesis of oestrogen [43,47,48]. Concentrations of parabens, comparable to levels measured in breast tissues, may increase the expression of oestrogen and progesterone receptors, suggesting that they may be implicated in breast cancer at biologically relevant doses [39]. Parabens may also increase oestrogen production in breast cancer cells, whilst reducing it in non-cancerous breast cells [2]. In addition to this, parabens may also block the conversion of oestradiol

to the weaker form (oestrone), thus increasing oestrogen levels [43]. This mechanism may be particularly relevant in post-menopause, when oestrogen levels in the breast are regulated by the breast tissue [2], and no longer by the ovary, especially considering that parabens can accumulate in the breast [30–32].

In addition to cell proliferation, parabens may prevent the death of cancer cells (evasion of apoptosis) [38] and increase the invasion and migration of breast cancer cells [40,44], which are essential for the spread of the tumour to other parts of the body.

5.2 Animal studies

Exposure to EDCs with oestrogenic activity can be particularly harmful during certain life stages where we may be more susceptible to chemicals (read our [Critical Windows of Susceptibility for Breast Development](#) review). In some of these stages, the breast may also be more sensitive to hormonal interference as it undergoes rapid development [56].

Studies in animals have revealed that exposure to parabens during in utero development and puberty may affect the mammary gland and increase the number of terminal end buds (TEBs), which are usually the site where tumours start [57,58]. During pregnancy and lactation (breastfeeding), parabens may alter the morphology of the maternal mammary gland [57,59], whilst in adult female rodents they may increase the risk of mammary tumour and metastasis (spread of cancer cells to other tissues) [58].

5.3 Epidemiological studies

Whilst cell and animal studies suggest a possible link between parabens and breast cancer, human studies (also known as epidemiological studies) are largely inconclusive. One study showed a higher risk of breast cancer for women with the highest levels of parabens, especially for healthy-weight individuals (BMI < 25 mg/m²) [60]. In another study exposure to parabens was negatively associated with breast cancer in postmenopausal women [61], whilst a third study found no link between the chemicals and the disease [62].

The differences in the results across these studies may be explained, at least partially, by the different methodologies used. For instance, in one study current levels of EDCs were compared with previous cancer diagnoses [62], whilst another study used parabens levels pre-diagnosis [61]. A fourth study considered whether the effect of parabens on breast cancer risk is different based on DNA methylation [63], a process where methyl groups (Me) are added to the DNA. When the DNA has a high number of methylated genes is called “hypermethylated”, whilst “hypomethylation” is when the DNA has a lower number of methylated genes (Figure 4). DNA hypomethylation is a characteristic of breast cancer and it can increase DNA instability making carcinogens more potent. In this study, exposure to parabens was found to increase breast cancer risk in women with DNA hypomethylation, compared to participants with hypermethylated DNA [63].




Figure 4. DNA hypermethylation is when the DNA has many methyl (Me) groups attached to it, while hypomethylation is when the DNA lacks most of the methyl groups. With decreasing DNA methylation the DNA instability and susceptibility to cancer increase. Created with BioRender.com

A few epidemiological studies have also evaluated exposure to parabens in relation to other breast cancer risk factors, such as hormone levels and puberty onset. In premenopausal women, parabens, and mixtures of these with other EDCs, were shown to increase oestrogen and progesterone levels, which may influence breast cancer risk [64]. Another study found that exposure to parabens during childhood may be linked to early puberty, which may then increase breast cancer risk later in life [20,21].

Overall, current studies present many limitations, such as evaluating exposure levels only after diagnosis and not considering all the possible risk factors that may influence breast cancer [60,62,63]. Studies that measure exposure years before diagnosis should be preferred when trying to determine if there is an association between paraben exposure and breast cancer.

Table 1. List of parabens and their regulatory status in the EU and UK, according to the Cosmetic regulations and REACH framework. This includes, whether parabens are officially recognised to have endocrine disrupting properties; whether they are allowed in cosmetics (Annex V) or banned (Annex II); whether they are in the Candidate List of Substances of Very High Concern (SVHC).

Paraben*	Endocrine disruptor** [67]	EU cosmetic regulation [70,71]	UK cosmetic regulation [66,72]	EU Candidate List of SVHC [69]	UK Candidate List of SVHC [68]
para-Hydroxybenzoic acid	-	Annex V	Annex V	No	No
Methylparaben	Under assessment (EU)	Annex V	Annex V	No	No
Ethylparaben	-	Annex V	Annex V	No	No
Propylparaben	Yes (EU)	Annex V	Annex V	No	No
Isopropylparaben	-	Annex II	Annex II	No	No
Butylparaben	Yes (EU, UK)	Annex V	Annex V	Yes	Yes
Isobutylparaben	Yes (EU)	Annex II	Annex II	Yes	No
Pentylparaben	-	Annex II	Annex II	No	No
Phenylparaben	-	Annex II	Annex II	No	No
Benzylparaben	-	Annex II	Annex II	No	No

*other parabens may exist; ** not all parabens have been evaluated.

6. Regulations

Paraben regulations in the UK are largely consistent with the current EU stance, as they were introduced before Brexit (Table 1). In 2014, five parabens were banned from cosmetics (Cosmetic Regulation, Annex II), due to insufficient information on their safety [65].

On the other hand, para-hydroxybenzoic acid and 4 parabens (methylparaben, ethylparaben, propyl-paraben and butylparaben) are allowed preservatives in cosmetics and personal care products (Cosmetic Regulation, Annex V) [66]. This is concerning because butylparaben and propylparaben have been officially recognised to be EDCs by the EU. In 2020, butylparaben was also added to the Candidate List of Substances of Very

High Concern in the EU and UK (SVHC) [67,68]. The Candidate List is part of REACH, a regulatory framework separate from the Cosmetic Regulation, and contains chemicals selected to be phased out due to their harmful effects [68,69].

7. Conclusion

Parabens are EDCs used as preservatives in cosmetics, personal care products and occasionally in food. Exposure to these chemicals is widespread in the population and higher for women, possibly due to the use of cosmetics. Parabens can be absorbed through the skin and have been measured in many body fluids and

tissues, including cancerous and non-cancerous breast tissue. They can affect hormones by mimicking oestrogen and binding to its receptors, or by interfering with its levels. While some studies have shown that parabens have oestrogenic effects only at high concentrations, others have observed negative effects at doses relevant to human exposure, especially when in mixtures with other parabens or EDCs. In animals, exposure to parabens during in utero development, puberty and pregnancy has been linked to changes to the mammary gland and an increased risk of mammary tumours. Whilst

laboratory studies suggest that parabens may play a role in breast cancer development and progression, human studies are limited and so far inconclusive on the link between parabens and breast cancer. Nonetheless, there is enough evidence that parabens can have harmful effects to justify a precautionary approach. People can reduce their exposure by choosing paraben-free cosmetics and personal care products, but further regulations are needed to address parabens. Breast Cancer UK is calling for a phasing out of EDCs and removing them from non-essential-use products.

References

- [1] Nowak K, Ratajczak-Wrona W, Górská M, Jabłońska E. Parabens and their effects on the endocrine system. *Mol Cell Endocrinol* 2018;474:238–51. <https://doi.org/10.1016/j.mce.2018.03.014>.
- [2] Hager E, Chen J, Zhao L. Minireview: Parabens Exposure and Breast Cancer. *Int J Environ Res Public Health* 2022;19:1873. <https://doi.org/10.3390/ijerph19031873>.
- [3] Darbre PD. Personal Care Products and Human Health. 2023. <https://doi.org/10.1016/C2021-0-01848-4>.
- [4] Svobodova L, Kejlova K, Rucki M, Chrz J, Kubincova P, Dvorakova M, et al. Health safety of parabens evaluated by selected in vitro methods. *Regulatory Toxicology and Pharmacology* 2023;137:105307. <https://doi.org/10.1016/j.yrtph.2022.105307>.
- [5] Wei F, Mortimer M, Cheng H, Sang N, Guo L-H. Parabens as chemicals of emerging concern in the environment and humans: A review. *Science of The Total Environment* 2021;778:146150. <https://doi.org/10.1016/j.scitotenv.2021.146150>.
- [6] European Commission. Uniform Sanitary and Epidemiological and Hygienic Requirements for Goods Subject to Sanitary and Epidemiological Supervision. Chapter II. Part 22. Safety Requirements for Food Additives and Flavourings 2011. https://food.ec.europa.eu/document/download/d12ae437-8d70-4198-8335-899f6519c22c_en?filename=ia_eu-ru_sps-req_req_san-epi_chap-2_22_en.pdf (accessed July 23, 2024).
- [7] Food Standards Agency. Approved additives and E numbers 2024. <https://www.food.gov.uk/business-guidance/approved-additives-and-e-numbers> (accessed July 22, 2024).
- [8] Stanfield Z, Setzer RW, Hull V, Sayre RR, Isaacs KK, Wambaugh JF. Characterizing Chemical Exposure Trends from NHANES Urinary Biomonitoring Data. *Environ Health Perspect* 2024;132:017009. <https://doi.org/10.1289/EHP12188>.
- [9] Huang K, Zhang X, Wang B, Wang X, You Y, Tang H, et al. Accurate assessment of parabens exposure in healthy Chinese female adults: Findings from a multi-pathway exposure assessment coupled with intervention study. *Environ Res* 2021;193:110540. <https://doi.org/10.1016/j.envres.2020.110540>.
- [10] Janjua NR, Frederiksen H, Skakkebaek NE, Wulf HC, Andersson A-M. Urinary excretion of phthalates and paraben after repeated whole-body topical application in humans. *Int J Androl* 2008;31:118–30. <https://doi.org/10.1111/j.1365-2605.2007.00841.x>.

- [11] Darbre PD, Harvey PW. Paraben esters: review of recent studies of endocrine toxicity, absorption, esterase and human exposure, and discussion of potential human health risks. *Journal of Applied Toxicology* 2008;28:561–78. <https://doi.org/10.1002/jat.1358>.
- [12] Koch HM, Aylward LL, Hays SM, Smolders R, Moos RK, Cocker J, et al. Inter- and intra-individual variation in urinary biomarker concentrations over a 6-day sampling period. Part 2: Personal care product ingredients. *Toxicol Lett* 2014;231:261–9. <https://doi.org/10.1016/j.toxlet.2014.06.023>.
- [13] Iribarne-Durán LM, Serrano L, Peinado FM, Peña-Caballero M, Hurtado JA, Vela-Soria F, et al. Biomonitoring bisphenols, parabens, and benzophenones in breast milk from a human milk bank in Southern Spain. *Science of The Total Environment* 2022;830:154737. <https://doi.org/10.1016/j.scitotenv.2022.154737>.
- [14] Barr L, Metaxas G, Harbach CAJ, Savoy LA, Darbre PD. Measurement of paraben concentrations in human breast tissue at serial locations across the breast from axilla to sternum. *Journal of Applied Toxicology* 2012;32:219–32. <https://doi.org/10.1002/jat.1786>.
- [15] Vela-Soria F, Rodríguez I, Ballesteros O, Zafra-Gómez A, Ballesteros L, Cela R, et al. Simplified matrix solid phase dispersion procedure for the determination of parabens and benzophenone-ultraviolet filters in human placental tissue samples. *J Chromatogr A* 2014;1371:39–47. <https://doi.org/10.1016/j.chroma.2014.10.063>.
- [16] Hines EP, Mendola P, von Ehrenstein OS, Ye X, Calafat AM, Fenton SE. Concentrations of environmental phenols and parabens in milk, urine and serum of lactating North Carolina women. *Reproductive Toxicology* 2015;54:120–8. <https://doi.org/10.1016/j.reprotox.2014.11.006>.
- [17] Towers C V, Terry PD, Lewis D, Howard B, Chambers W, Armistead C, et al. Transplacental passage of antimicrobial paraben preservatives. *J Expo Sci Environ Epidemiol* 2015;25:604–7. <https://doi.org/10.1038/jes.2015.27>.
- [18] Fisher M, MacPherson S, Braun JM, Hauser R, Walker M, Feeley M, et al. Paraben Concentrations in Maternal Urine and Breast Milk and Its Association with Personal Care Product Use. *Environ Sci Technol* 2017;51:4009–17. <https://doi.org/10.1021/acs.est.6b04302>.
- [19] Shekhar S, Sood S, Showkat S, Lite C, Chandrasekhar A, Vairamani M, et al. Detection of phenolic endocrine disrupting chemicals (EDCs) from maternal blood plasma and amniotic fluid in Indian population. *Gen Comp Endocrinol* 2017;241:100–7. <https://doi.org/10.1016/j.ygcen.2016.05.025>.
- [20] Harley KG, Berger KP, Kogut K, Parra K, Lustig RH, Greenspan LC, et al. Association of phthalates, parabens and phenols found in personal care products with pubertal timing in girls and boys. *Human Reproduction* 2019;34:109–17. <https://doi.org/10.1093/humrep/dey337>.
- [21] Rivera-Núñez Z, Kinkade CW, Zhang Y, Rockson A, Bandera E V, Llanos AAM, et al. Phenols, Parabens, Phthalates and Puberty: a Systematic Review of Synthetic Chemicals Commonly Found in Personal Care Products and Girls' Pubertal Development. *Curr Environ Health Rep* 2022;9:517–34. <https://doi.org/10.1007/s40572-022-00366-4>.
- [22] Carmona E, Andreu V, Picó Y. Occurrence of acidic pharmaceuticals and personal care products in Turia River Basin: From waste to drinking water. *Science of The Total Environment* 2014;484:53–63. <https://doi.org/10.1016/j.scitotenv.2014.02.085>.
- [23] Kasprzyk-Hordern B, Dinsdale RM, Guwy AJ. The occurrence of pharmaceuticals, personal care products, endocrine disruptors and illicit drugs in surface water in South Wales, UK. *Water Res* 2008;42:3498–518. <https://doi.org/10.1016/j.watres.2008.04.026>.
- [24] Stuart M, Lapworth D, Crane E, Hart A. Review of risk from potential emerging contaminants in UK groundwater. *Science of The Total Environment* 2012;416:1–21. <https://doi.org/10.1016/j.scitotenv.2011.11.072>.
- [25] Viglino L, Prévost M, Sauvé S. High throughput analysis of solid-bound endocrine disruptors by LDTD-APCI-MS/MS. *Journal of Environmental Monitoring* 2011;13:583–90. <https://doi.org/10.1039/C0EM00550A>.
- [26] Xue J, Sasaki N, Elangovan M, Diamond G, Kannan K. Elevated Accumulation of Parabens and their Metabolites in Marine Mammals from the United States Coastal Waters. *Environ Sci Technol* 2015;49:12071–9. <https://doi.org/10.1021/acs.est.5b03601>.

- [27] Canosa P, Rodríguez I, Rubí E, Cela R. Determination of Parabens and Triclosan in Indoor Dust Using Matrix Solid-Phase Dispersion and Gas Chromatography with Tandem Mass Spectrometry. *Anal Chem* 2007;79:1675–81. <https://doi.org/10.1021/ac061896e>.
- [28] Rudel RA, Dodson RE, Perovich LJ, Morello-Frosch R, Camann DE, Zuniga MM, et al. Semivolatile Endocrine-Disrupting Compounds in Paired Indoor and Outdoor Air in Two Northern California Communities. *Environ Sci Technol* 2010;44:6583–90. <https://doi.org/10.1021/es100159c>.
- [29] Tran TM, Minh TB, Kumosani TA, Kannan K. Occurrence of phthalate diesters (phthalates), p-hydroxybenzoic acid esters (parabens), bisphenol A diglycidyl ether (BADGE) and their derivatives in indoor dust from Vietnam: Implications for exposure. *Chemosphere* 2016;144:1553–9. <https://doi.org/10.1016/j.chemosphere.2015.10.028>.
- [30] Darbre PD, Aljarrah A, Miller WR, Coldham NG, Sauer MJ, Pope GS. Concentrations of parabens in human breast tumours. *Journal of Applied Toxicology* 2004;24:5–13. <https://doi.org/10.1002/jat.958>.
- [31] Shen X, Liang J, Zheng L, Wang H, Wang Z, Ji Q, et al. Ultrasound-assisted dispersive liquid-liquid microextraction followed by gas chromatography-mass spectrometry for determination of parabens in human breast tumor and peripheral adipose tissue. *Journal of Chromatography B* 2018;1096:48–55. <https://doi.org/10.1016/j.jchromb.2018.08.004>.
- [32] Downs CA, Amin MM, Tabatabaeian M, Chavoshani A, Amjadi E, Afshari A, et al. Parabens preferentially accumulate in metastatic breast tumors compared to benign breast tumors and the association of breast cancer risk factors with paraben accumulation. *Environmental Advances* 2023;11:100325. <https://doi.org/10.1016/j.envadv.2022.100325>.
- [33] Pugazhendhi D, Pope GS, Darbre PD. Oestrogenic activity of p-hydroxybenzoic acid (common metabolite of paraben esters) and methylparaben in human breast cancer cell lines. *Journal of Applied Toxicology* 2005;25:301–9. <https://doi.org/https://doi.org/10.1002/jat.1066>.
- [34] Klinge CM. Estrogen receptor interaction with estrogen response elements. *Nucleic Acids Res* 2001;29:2905–19. <https://doi.org/10.1093/nar/29.14.2905>.
- [35] Yue W, Wang J-P, Li Y, Fan P, Liu G, Zhang N, et al. Effects of estrogen on breast cancer development: Role of estrogen receptor independent mechanisms. *Int J Cancer* 2010;127:1748–57. <https://doi.org/https://doi.org/10.1002/ijc.25207>.
- [36] Nounu A, Kar SP, Relton CL, Richmond RC. Sex steroid hormones and risk of breast cancer: a two-sample Mendelian randomization study. *Breast Cancer Research* 2022;24:66. <https://doi.org/10.1186/s13058-022-01553-9>.
- [37] Kay JE, Brody JG, Schwarzman M, Rudel RA. Application of the Key Characteristics Framework to Identify Potential Breast Carcinogens Using Publicly Available in Vivo, in Vitro, and in Silico Data. *Environ Health Perspect* 2024;132:017002. <https://doi.org/10.1289/EHP13233>.
- [38] Wróbel AM, Gregoraszczyk EŁ. Action of methyl-, propyl- and butylparaben on GPR30 gene and protein expression, cAMP levels and activation of ERK1/2 and PI3K/Akt signaling pathways in MCF-7 breast cancer cells and MCF-10A non-transformed breast epithelial cells. *Toxicol Lett* 2015;238:110–6. <https://doi.org/10.1016/j.toxlet.2015.08.001>.
- [39] Wróbel AM, Gregoraszczyk EŁ. Actions of methyl-, propyl- and butylparaben on estrogen receptor- α and - β and the progesterone receptor in MCF-7 cancer cells and non-cancerous MCF-10A cells. *Toxicol Lett* 2014;230:375–81. <https://doi.org/10.1016/j.toxlet.2014.08.012>.
- [40] Khanna S, Dash PR, Darbre PD. Exposure to parabens at the concentration of maximal proliferative response increases migratory and invasive activity of human breast cancer cells in vitro. *Journal of Applied Toxicology* 2014;34:1051–9. <https://doi.org/10.1002/jat.3003>.
- [41] Pop A, Drugan T, Gutleb AC, Lupu D, Cherfan J, Loghin F, et al. Estrogenic and anti-estrogenic activity of butylparaben, butylated hydroxyanisole, butylated hydroxytoluene and propyl gallate and their binary mixtures on two estrogen responsive cell lines (T47D-Kbluc, MCF-7). *Journal of Applied Toxicology* 2018;38:944–57. <https://doi.org/10.1002/jat.3601>.
- [42] Dairkee SH, Luciani-Torres G, Moore DH, Jaffee IM, Goodson III WH. A Ternary Mixture of Common Chemicals Perturbs Benign Human Breast Epithelial Cells More Than the Same Chemicals Do Individually. *Toxicological Sciences* 2018;165:131–44. <https://doi.org/10.1093/toxsci/kfy126>.

- [43] Engeli RT, Rohrer SR, Vuorinen A, Herdinger S, Kaserer T, Leugge S, et al. Interference of Paraben Compounds with Estrogen Metabolism by Inhibition of 17 β -Hydroxysteroid Dehydrogenases. *Int J Mol Sci* 2017;18:2007. <https://doi.org/10.3390/ijms18092007>.
- [44] Wang L, Chen L, Schlenk D, Li F, Liu J. Parabens promotes invasive properties of multiple human cells: A potential cancer-associated adverse outcome pathway. *Science of The Total Environment* 2024;926:172015. <https://doi.org/10.1016/j.scitotenv.2024.172015>.
- [45] Kim J-Y, Park Y, Lee S-H, Park E, Lee H. Comparative study on estrogen receptor alpha dimerization and transcriptional activity of parabens. *Toxicol Res* 2024;40:153–61. <https://doi.org/10.1007/s43188-023-00212-1>.
- [46] Okubo T, Yokoyama Y, Kano K, Kano I. ER-dependent estrogenic activity of parabens assessed by proliferation of human breast cancer MCF-7 cells and expression of ER α and PR. *Food and Chemical Toxicology* 2001;39:1225–32. [https://doi.org/10.1016/S0278-6915\(01\)00073-4](https://doi.org/10.1016/S0278-6915(01)00073-4).
- [47] Elsehly WM, Mourad GM, Mehanna RA, Kholief MA, El-Nikhely NA, Awaad AK, et al. The potential implications of estrogenic and antioxidant-dependent activities of high doses of methyl paraben on MCF7 breast cancer cells. *J Biochem Mol Toxicol* 2022;36:e23012. <https://doi.org/10.1002/jbt.23012>.
- [48] Liang J, Liu QS, Ren Z, Min K, Yang X, Hao F, et al. Studying paraben-induced estrogen receptor- and steroid hormone-related endocrine disruption effects via multi-level approaches. *Science of The Total Environment* 2023;869:161793. <https://doi.org/10.1016/j.scitotenv.2023.161793>.
- [49] Tapia JL, McDonough JC, Cauble EL, Gonzalez CG, Teteh DK, Treviño LS. Parabens Promote Protumorigenic Effects in Luminal Breast Cancer Cell Lines With Diverse Genetic Ancestry. *J Endocr Soc* 2023;7. <https://doi.org/10.1210/jendso/bvad080>.
- [50] Terasaka S, Inoue A, Tanji M, Kiyama R. Expression profiling of estrogen-responsive genes in breast cancer cells treated with alkylphenols, chlorinated phenols, parabens, or bis- and benzoylphenols for evaluation of estrogenic activity. *Toxicol Lett* 2006;163:130–41. <https://doi.org/https://doi.org/10.1016/j.toxlet.2005.10.005>.
- [51] Chen Y, Zhao C, Zheng J, Su N, Ji H. Discovery of the mechanism of n-propylparaben-promoting the proliferation of human breast adenocarcinoma cells by activating human estrogen receptors via metabolomics analysis. *Hum Exp Toxicol* 2023;42:09603271231171648. <https://doi.org/10.1177/09603271231171648>.
- [52] Dagher Z, Borgie M, Magdalou J, Chahine R, Greige-Gerges H. p-Hydroxybenzoate esters metabolism in MCF7 breast cancer cells. *Food and Chemical Toxicology* 2012;50:4109–14. <https://doi.org/10.1016/j.fct.2012.08.013>.
- [53] Sala-Hamrick KE, Tapaswi A, Polemi KM, Nguyen VK, Colacino JA. High-Throughput Transcriptomics of Nontumorigenic Breast Cells Exposed to Environmentally Relevant Chemicals. *Environ Health Perspect* 2024;132:047002. <https://doi.org/10.1289/EHP12886>.
- [54] Janjua NR, Mortensen GK, Andersson A-M, Kongshoj B, Wulf HC. Systemic Uptake of Diethyl Phthalate, Dibutyl Phthalate, and Butyl Paraben Following Whole-Body Topical Application and Reproductive and Thyroid Hormone Levels in Humans. *Environ Sci Technol* 2007;41:5564–70. <https://doi.org/10.1021/es0628755>.
- [55] Charles AK, Darbre PD. Combinations of parabens at concentrations measured in human breast tissue can increase proliferation of MCF-7 human breast cancer cells. *Journal of Applied Toxicology* 2013;33:390–8. <https://doi.org/10.1002/jat.2850>.
- [56] Gopalakrishnan K, Teitelbaum SL, Lambertini L, Wetmur J, Manservigi F, Falcioni L, et al. Changes in mammary histology and transcriptome profiles by low-dose exposure to environmental phenols at critical windows of development. *Environ Res* 2017;152:233–43. <https://doi.org/10.1016/j.envres.2016.10.021>.
- [57] Boberg J, Axelstad M, Svingen T, Mandrup K, Christiansen S, Vinggaard AM, et al. Multiple Endocrine Disrupting Effects in Rats Perinatally Exposed to Butylparaben. *Toxicological Sciences* 2016;152:244–56. <https://doi.org/10.1093/toxsci/kfw079>.
- [58] Tong JH, Elmore S, Huang S-S, Tachachartvanich P, Manz K, Pennell K, et al. Chronic Exposure to Low Levels of Parabens Increases Mammary Cancer Growth and Metastasis in Mice. *Endocrinology* 2023;164:bqad007. <https://doi.org/10.1210/endocr/bqad007>.

- [59] Mogus JP, Laplante CD, Bansal R, Matouskova K, Schneider BR, Daniele E, et al. Exposure to Propylparaben During Pregnancy and Lactation Induces Long-Term Alterations to the Mammary Gland in Mice. *Endocrinology* 2021;162. <https://doi.org/10.1210/ENDOCR/BQAB041>.
- [60] Parada H, Gammon MD, Ettore HL, Chen J, Calafat AM, Neugut AI, et al. Urinary concentrations of environmental phenols and their associations with breast cancer incidence and mortality following breast cancer. *Environ Int* 2019;130:104890. <https://doi.org/10.1016/j.envint.2019.05.084>.
- [61] Wu AH, Franke AA, Wilkens LR, Tseng C, Conroy SM, Li Y, et al. Risk of breast cancer and prediagnostic urinary excretion of bisphenol A, triclosan and parabens: The Multiethnic Cohort Study. *Int J Cancer* 2021;149:1426–34. <https://doi.org/10.1002/ijc.33692>.
- [62] Cathey AL, Nguyen VK, Colacino JA, Woodruff TJ, Reynolds P, Aung MT. Exploratory profiles of phenols, parabens, and per- and poly-fluoroalkyl substances among NHANES study participants in association with previous cancer diagnoses. *J Expo Sci Environ Epidemiol* 2023;33:687–98. <https://doi.org/10.1038/s41370-023-00601-6>.
- [63] Parada Jr. H, Sahrai L, Wolff MS, Santella RM, Chen J, Neugut AI, et al. Urinary parabens and breast cancer risk: Modification by LINE-1 and LUMA global DNA methylation, and associations with breast cancer defined by tumor promoter methylation status. *Mol Carcinog* 2022;61:1002–15. <https://doi.org/10.1002/mc.23456>.
- [64] Pollack AZ, Mumford SL, Krall JR, Carmichael AE, Sjaarda LA, Perkins NJ, et al. Exposure to bisphenol A, chlorophenols, benzophenones, and parabens in relation to reproductive hormones in healthy women: A chemical mixture approach. *Environ Int* 2018;120:137–44. <https://doi.org/10.1016/j.envint.2018.07.028>.
- [65] European Union. Commission Regulation (EU) No 1004/2014 of 18 September 2014 amending Annex V to Regulation (EC) No 1223/2009 of the European Parliament and of the Council on cosmetic products Text with EEA relevance 2014. <https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32014R1004> (accessed July 23, 2024).
- [66] UK Government. Regulation (EC) No 1223/2009. Annex V List Of Preservatives Allowed In Cosmetic Products 2022. <https://www.legislation.gov.uk/eur/2009/1223/annex/V/2022-10-15> (accessed July 23, 2024).
- [67] European Chemicals Agency. Endocrine disruptor assessment list 2024. <https://echa.europa.eu/ed-assessment> (accessed July 23, 2024).
- [68] Health and Safety Executive. UK REACH Candidate List of substances of very high concern (SVHCs) for authorisation <https://www.hse.gov.uk/reach/candidate-list.htm> (accessed July 23, 2024).
- [69] European Chemicals Agency. Candidate List of substances of very high concern for Authorisation 2024. <https://echa.europa.eu/candidate-list-table> (accessed July 23, 2024).
- [70] European Commission. Annex V List Of Preservatives Allowed In Cosmetic Products <https://ec.europa.eu/growth/tools-databases/cosing/reference/annexes/list/V> (accessed July 23, 2024).
- [71] European Commission. Annex II List Of Substances Prohibited In Cosmetic Products. <https://ec.europa.eu/growth/tools-databases/cosing/reference/annexes/list/II> (accessed July 23, 2024).
- [72] UK Government. Regulation (EC) No 1223/2009 of the European Parliament and of the Council. Annex II List Of Substances Prohibited In Cosmetic Products 2022. <https://www.legislation.gov.uk/eur/2009/1223/annex/II> (accessed July 23, 2024).

About Breast Cancer UK

Who we are?

Breast Cancer UK aims to prevent breast cancer through scientific research, collaboration, education and policy change. We educate and raise awareness of the risk factors for breast cancer and provide practical information to help people reduce these risks. We campaign to ensure government policies support the prevention of breast cancer. And we fund scientific research that helps to better understand what risk factors contribute to breast cancer, and how to address them. For further information on breast cancer risk factors please visit our website www.breastcanceruk.org.uk

To view this information in a more accessible format or to provide feedback, please contact us.

This review is for information purposes only and does not cover all breast cancer risks. Nor does it constitute medical advice and should not be used as an alternative to professional care. If you detect a lump or have any concerns, seek advice from your GP. Breast Cancer UK has made every effort to ensure the content of this leaflet is correct at the time of publishing but no warranty is given to that effect nor any liability accepted for any loss or damage arising from its use.

Version: 2.0

Date: 11/11/2024

Next update: 11/11/2027

We welcome your feedback, if you have any comments or suggestions about this review please contact us at info@breastcanceruk.org.uk or on 0208 1327088.

www.breastcanceruk.org.uk

 @BreastCancer_UK
 @breastcanceruk
 @breastcanceruk
 @Breast Cancer UK

